ATE470447T1 - Depsipetid und kongenere davon für den einsatz als immunsuppressiva zur vorbeugung und behandlung von abstossreaktionen infolge einer transplantation und zur induktion des apoptosis in aktivierten cd4 oder cd8 t-zellen - Google Patents

Depsipetid und kongenere davon für den einsatz als immunsuppressiva zur vorbeugung und behandlung von abstossreaktionen infolge einer transplantation und zur induktion des apoptosis in aktivierten cd4 oder cd8 t-zellen

Info

Publication number
ATE470447T1
ATE470447T1 AT07002930T AT07002930T ATE470447T1 AT E470447 T1 ATE470447 T1 AT E470447T1 AT 07002930 T AT07002930 T AT 07002930T AT 07002930 T AT07002930 T AT 07002930T AT E470447 T1 ATE470447 T1 AT E470447T1
Authority
AT
Austria
Prior art keywords
congeners
prevention
treatment
depsipetide
immunosupressives
Prior art date
Application number
AT07002930T
Other languages
English (en)
Inventor
Skov Soren
Original Assignee
Cyclacel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26865325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE470447(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cyclacel Pharmaceuticals Inc filed Critical Cyclacel Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE470447T1 publication Critical patent/ATE470447T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT07002930T 1999-12-08 2000-12-06 Depsipetid und kongenere davon für den einsatz als immunsuppressiva zur vorbeugung und behandlung von abstossreaktionen infolge einer transplantation und zur induktion des apoptosis in aktivierten cd4 oder cd8 t-zellen ATE470447T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16973199P 1999-12-08 1999-12-08
US19358200P 2000-03-30 2000-03-30

Publications (1)

Publication Number Publication Date
ATE470447T1 true ATE470447T1 (de) 2010-06-15

Family

ID=26865325

Family Applications (3)

Application Number Title Priority Date Filing Date
AT00983997T ATE269354T1 (de) 1999-12-08 2000-12-06 Depsipeptide und deren analoge zur verwendung als immunosuppressiva
AT07002930T ATE470447T1 (de) 1999-12-08 2000-12-06 Depsipetid und kongenere davon für den einsatz als immunsuppressiva zur vorbeugung und behandlung von abstossreaktionen infolge einer transplantation und zur induktion des apoptosis in aktivierten cd4 oder cd8 t-zellen
AT04007814T ATE353663T1 (de) 1999-12-08 2000-12-06 Verwendung von depsipeptide und deren analoge als immunosuppressiva zur behandlung von infektionskrankheiten, autoimmunerkrankungen, allergien und hyperproliferativer hautkrankheiten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00983997T ATE269354T1 (de) 1999-12-08 2000-12-06 Depsipeptide und deren analoge zur verwendung als immunosuppressiva

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04007814T ATE353663T1 (de) 1999-12-08 2000-12-06 Verwendung von depsipeptide und deren analoge als immunosuppressiva zur behandlung von infektionskrankheiten, autoimmunerkrankungen, allergien und hyperproliferativer hautkrankheiten

Country Status (16)

Country Link
US (2) US6403555B1 (de)
EP (3) EP1246839B1 (de)
JP (4) JP4824890B2 (de)
KR (1) KR20020062956A (de)
CN (1) CN1414971A (de)
AT (3) ATE269354T1 (de)
AU (1) AU762525B2 (de)
BR (1) BR0016154A (de)
CA (1) CA2393682C (de)
DE (3) DE60011678T2 (de)
DK (1) DK1438966T3 (de)
ES (3) ES2282751T3 (de)
HK (1) HK1049849B (de)
IL (2) IL149995A0 (de)
PT (1) PT1438966E (de)
WO (1) WO2001042282A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
US8119159B2 (en) 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US7396665B2 (en) 2000-09-01 2008-07-08 Astellas Pharma, Inc. Method of producing FR901228
WO2002055017A2 (en) * 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
US6632553B2 (en) * 2001-03-27 2003-10-14 Mti Microfuel Cells, Inc. Methods and apparatuses for managing effluent products in a fuel cell system
RU2298414C2 (ru) * 2001-08-21 2007-05-10 Астеллас Фарма Инк. Медицинское применение ингибитора гистоновой дезацетилазы и способ оценки его противоопухолевого действия
US8163764B2 (en) * 2002-04-26 2012-04-24 Asan Laboratories Company (Cayman) Limited Skincare methods
US8883148B2 (en) * 2002-04-26 2014-11-11 Asan Laboratories Company (Cayman), Limited Prevention of joint destruction
US6809118B2 (en) * 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
US8846039B2 (en) * 2002-04-26 2014-09-30 Asan Laboratories Company (Cayman), Limited Method for ameliorating pruritus
US20060275370A1 (en) * 2002-07-25 2006-12-07 Yih-Lin Chung Method and compositions for treatment of epithelial damage
US8946295B2 (en) * 2002-07-25 2015-02-03 Sunny Pharmtech Inc. Histone hyperacetylating agents for promoting wound healing and preventing scar formation
CA2495354A1 (en) * 2002-08-20 2004-03-04 Yamanouchi Pharmaceutical Co., Ltd. An agent for inhibiting articular cartilage extracellular matrix degradation
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1638541B1 (de) * 2003-06-27 2010-05-19 Astellas Pharma Inc. Therapeutisches mittel für ein weichteilsarkom
CN1871034B (zh) * 2003-07-09 2011-07-06 亨利福特保健系统公司 用新型腺病毒治疗癌症的方法和组合物
DE602004027824D1 (de) * 2003-09-25 2010-08-05 Astellas Pharma Inc Antitumorales mittel mit einem histon-deacetylase-hemmer und einem topoisomerase-ii-hemmer
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
US20050187148A1 (en) * 2004-02-25 2005-08-25 Yoshinori Naoe Antitumor agent
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
WO2006055621A2 (en) * 2004-11-17 2006-05-26 The University Of Chicago Histone deacetylase inhibitors and methods of use
US7642275B2 (en) 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
GB0511266D0 (en) * 2005-06-02 2005-07-13 Trust Chemical compounds
CA2615105A1 (en) * 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2621560A1 (en) * 2005-09-07 2007-03-15 Braincells, Inc. Modulation of neurogenesis by hdac inhibition
CA2630216A1 (en) * 2005-11-18 2007-05-31 Gloucester Pharmaceuticals, Inc. Metabolite derivatives of the hdac inhibitor fk228
EP1976835A2 (de) * 2006-01-13 2008-10-08 Takeda San Diego, Inc. Histondeacetylase-inhibitoren
BRPI0710503A2 (pt) 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
US9539303B2 (en) * 2006-04-24 2017-01-10 Celgene Corporation Treatment of Ras-expressing tumors
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
WO2007146234A2 (en) * 2006-06-09 2007-12-21 Merrion Research Ii Limited Solid oral dosage form containing an enhancer
US7883855B2 (en) 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
JP2010503710A (ja) 2006-09-18 2010-02-04 ラプトール ファーマシューティカル インコーポレイテッド 受容体関連タンパク質（ｒａｐ）結合体の投与による肝障害の処置
CA2670223A1 (en) * 2006-11-22 2008-05-29 Karus Therapeutics Limited Depsipeptides and their therapeutic use
GB0623388D0 (en) * 2006-11-23 2007-01-03 Univ Southampton Chemical compounds
US7914999B2 (en) 2006-12-29 2011-03-29 Abbott Laboratories Non-denaturing lysis reagent
EP2102230A2 (de) 2006-12-29 2009-09-23 Gloucester Pharmaceuticals, Inc. Reinigung von romidepsin
CN103497238A (zh) 2006-12-29 2014-01-08 细胞基因公司 制备Romidepsin
WO2008151306A1 (en) * 2007-06-05 2008-12-11 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Synthesis of cyclodepsipeptide compounds having antineoplastic and/or antimicrobial activity
GB0715750D0 (en) * 2007-08-13 2007-09-19 Karus Therapeutics Ltd Chemical compounds
WO2009078875A1 (en) * 2007-12-19 2009-06-25 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
US20090280169A1 (en) 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
WO2009141658A1 (en) * 2008-05-22 2009-11-26 Karus Therapeutics Limited Depsipeptides and their therapeutic use
WO2009141657A1 (en) * 2008-05-22 2009-11-26 Karus Therapeutics Limited Depsipeptides and their therapeutic use
ES2621849T3 (es) * 2009-06-26 2017-07-05 Sunny Pharmtech Inc. Método de tratamiento o mejora de toxicidades mucocutáneas u oculares.
TWI412359B (zh) * 2009-07-07 2013-10-21 Asan Lab Co Ltd 組織蛋白去乙醯酵素抑制劑在製備治療或減緩黏膜／皮膚或眼睛毒性或副作用之藥物的用途
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
CN103108648A (zh) 2010-07-12 2013-05-15 细胞基因公司 罗米地辛固体形式及其用途
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
EP2661273A4 (de) 2011-01-07 2014-06-04 Merrion Res Iii Ltd Pharmazeutische zusammensetzungen aus eisen zur oralen verabreichung
WO2013047509A1 (ja) * 2011-09-30 2013-04-04 国立大学法人東北大学 新規ホスファチジルイノシトール３キナーゼ阻害剤及び医薬組成物
CA2866392C (en) 2012-03-30 2023-10-24 Washington University Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
TWI702046B (zh) * 2013-07-19 2020-08-21 美商Ionis製藥公司 用於調節τ蛋白表現之組合物
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
KR20150140177A (ko) * 2014-06-05 2015-12-15 한미약품 주식회사 단백질 및 펩타이드의 면역원성을 감소시키는 방법
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
CN110760564A (zh) * 2019-10-16 2020-02-07 菲诺克生物科技(上海)有限公司 细胞周期检测方法及其所用试剂与试剂盒

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4268516A (en) 1978-10-11 1981-05-19 Pfizer Inc. [1]Benzothiopyrano[4,3-c]pyrazoles as immunoregulatory agents
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
GB8817743D0 (en) * 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
WO1993019778A1 (en) 1992-04-07 1993-10-14 The Scripps Research Institute Method for inducing tolerance to an antigen using butyrate
ZA946765B (en) 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US5591717A (en) 1994-04-06 1997-01-07 Rojko; Jennifer L. Branched apogenic peptide for inducing apoptosis
WO1995033823A1 (en) 1994-06-03 1995-12-14 The United States Of America, Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of t cells
WO1999014241A2 (en) 1997-09-17 1999-03-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US5843943A (en) 1994-12-29 1998-12-01 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US5962019A (en) 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5891653A (en) 1995-12-29 1999-04-06 Attfield; Derrick Cecil Method of suppressing graft rejection by means of stress proteins
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
CA2283161A1 (en) 1997-03-03 1998-09-11 Duke University Immunosuppression
DE19713626A1 (de) * 1997-04-02 1998-10-08 Bayer Ag Neue Thiodepsipeptide zur Bekämpfung von Endoparasiten und ein einfaches Verfahren zu ihrer Herstellung
WO1998046640A2 (en) 1997-04-15 1998-10-22 Coulter International Corp. Methods and compositions for inducing immunosuppression
NZ503061A (en) 1997-09-02 2001-08-31 Japan Energy Corp Cyclic tetrapeptide derivatives and use as anti-cancer agents
WO1999015174A1 (en) 1997-09-22 1999-04-01 Sloan-Kettering Institute For Cancer Research Reverse prenyl compounds as immunosuppressants
WO1999025703A1 (en) 1997-11-14 1999-05-27 Merck & Co., Inc. Immunosuppressant tetracyclic triterpenes
WO1999030730A1 (en) 1997-12-15 1999-06-24 Universite Laval Methods and compositions for improving the success of cell transplantation in a host
JPH11180873A (ja) 1997-12-22 1999-07-06 Kaken Shoyaku Kk ＮＦ−κＢ活性阻害剤
US6211145B1 (en) * 1997-12-25 2001-04-03 Nisshin Flour Milling Co., Ltd. Bicyclic depsipeptides
US6001815A (en) * 1997-12-25 1999-12-14 Nisshin Flour Milling Co., Ltd. Depsipeptides containing N-substituted glycine residue
EP0931792B1 (de) * 1998-01-27 2004-01-07 Nisshin Seifun Group Inc. Depsipeptide, die nicht-natürliche Aminosäuren enthalten
US6287843B1 (en) 1998-04-03 2001-09-11 Pioneer Hi-Bred International, Inc. Maize histone deacetylases and their use
DK1142905T3 (da) * 1999-01-13 2006-09-18 Astellas Pharma Inc Hidtil ukendt depsipeptidforbindelse

Also Published As

Publication number Publication date
WO2001042282A1 (en) 2001-06-14
DE60011678D1 (de) 2004-07-22
DE60033453D1 (de) 2007-03-29
US20020045575A1 (en) 2002-04-18
DK1438966T3 (da) 2007-06-11
ATE269354T1 (de) 2004-07-15
JP4824890B2 (ja) 2011-11-30
ES2282751T3 (es) 2007-10-16
US6403555B1 (en) 2002-06-11
JP2014205714A (ja) 2014-10-30
EP1779859A2 (de) 2007-05-02
US6548479B1 (en) 2003-04-15
AU762525B2 (en) 2003-06-26
EP1246839B1 (de) 2004-06-16
CN1414971A (zh) 2003-04-30
EP1438966B1 (de) 2007-02-14
AU2068001A (en) 2001-06-18
JP2003516418A (ja) 2003-05-13
ES2347284T3 (es) 2010-10-27
CA2393682A1 (en) 2001-06-14
KR20020062956A (ko) 2002-07-31
PT1438966E (pt) 2007-05-31
CA2393682C (en) 2012-01-31
WO2001042282A9 (en) 2002-05-30
HK1049849A1 (en) 2003-05-30
EP1438966A2 (de) 2004-07-21
ES2225282T3 (es) 2005-03-16
IL149995A (en) 2009-09-01
EP1779859A3 (de) 2007-05-16
HK1070268A1 (en) 2005-06-17
DE60044542D1 (de) 2010-07-22
JP2011084585A (ja) 2011-04-28
JP2013107902A (ja) 2013-06-06
HK1049849B (en) 2004-12-03
EP1779859B1 (de) 2010-06-09
EP1438966A3 (de) 2004-08-04
DE60011678T2 (de) 2005-07-14
EP1246839A1 (de) 2002-10-09
BR0016154A (pt) 2003-02-25
DE60033453T2 (de) 2007-11-29
ATE353663T1 (de) 2007-03-15
IL149995A0 (en) 2002-12-01

Similar Documents

Publication Publication Date Title
DE60044542D1 (de) Depsipetid und Kongenere davon für den Einsatz als Immunsuppressiva zur Vorbeugung und Behandlung von Abstossreaktionen infolge einer Transplantation und zur Induktion des Apoptosis in aktivierten CD4 oder CD8 T-Zellen
DE60119784D1 (de) Cyclische salen metall verbindungen als einfänger von sauerstoffradikalen und verwendbar als antioxidantien bei der behandlung und vorbeugung von krankheiten
WO2005086781A3 (en) Regulatory t cells and their use in immunotherapy and suppression of autoimmune responses
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
DE60026561D1 (de) Suppressorzellen zur prävention und behandlung von immunantworten bei transplantationen
ATE463256T1 (de) Mittel zur suppression von transplantat- abstossung
MXPA03008820A (es) Compuestos generadores de monoxido de carbono, para el tratamiento de desordenes vasculares, inflamatorios e inmunologicos.
MXPA05008973A (es) Metodo de tratamiento de rechazo de trasplante de cornea.
DE60231522D1 (de) Behandlung und vorbeugung von insulin-produzierende zelltransplantatabstossung
PL324424A1 (en) Therapeutic factors and autoimmunological diseases
ATE238061T1 (de) Verwendung von zytokinen und mitogenen für inhibierung von pathologischen immunantworten
ATE198990T1 (de) Konjugat zur behandlung von entzündlichen erkrankungen
ATE190839T1 (de) Verwendung von prodelphidinen zur behandlung von arthrose
ATE410172T1 (de) Verwendung eines analoges des vitamins d3 zur behandlung des autoimmunen diabetes
DE602005016729D1 (de) Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung
WO2003001877A3 (en) Methods for the diagnosis and treatment of cardiac tissue rejection
NO20022109D0 (no) Anvendelse av treosulfan for behandling av pasienter för benmargs- eller blodstamcelletansplantasjon
Fraser War Hospitals Supply Depots
DE69731284D1 (de) Verwendung Von Coxiella Bakterien zur Behandlung von Autoimmunkrankheiten
Rose Psychological Treatment Centres
Taylor How to Live in a Trap
Woodruff ImmunosurveiIlance
Gassel et al. Effect of neutral proteases from human granulocytes on colony forming cells in vitro
Oh et al. The role of cc chemokine receptor 5 (CCR5) and RANTES/CCl5 in skin allograft rejection
DE69619542D1 (de) Bismut enthaltende zusammensetzungen zur verhütung und behandlung gastrointestinaler beschwerden

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties